New approaches in the management of multiple sclerosis

References

• PithadiaAJainSNavaleAPathogenesis and treatment of multiple sclerosis (MS)Int J Neurol2009102120
   Google Scholar
• NoseworthyJHLucchinettiCRodriguezMWeinshenkerBGMultiple sclerosisN Engl J Med20003431393895211006371
   PubMed Web of Science ®Google Scholar
• CompstonAColesAMultiple sclerosisLancet200235993131221123111955556
   PubMed Web of Science ®Google Scholar
• PolmanCHReingoldSCEdanGDiagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”Ann Neurol200558684084616283615
   PubMed Web of Science ®Google Scholar
• McDonaldWICompstonAEdanGRecommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosisAnn Neurol200150112112711456302
   PubMed Web of Science ®Google Scholar
• MillerDHWeinshenkerBGFilippiMDifferential diagnosis of suspected multiple sclerosis: a consensus approachMult Scler20081491157117418805839
   PubMed Web of Science ®Google Scholar
• FrohmanEMGoodinDSCalabresiPAThe utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyNeurology200361560261112963748
   PubMed Web of Science ®Google Scholar
• GoodinDSBatesDTreatment of early multiple sclerosis: the value of treatment initiation after a first clinical episodeMult Scler200915101175118219737851
   PubMed Web of Science ®Google Scholar
• ComiGFilippiMBarkhofFEffect of early interferon treatment on conversion to definite multiple sclerosis: a randomised studyLancet200135792681576158211377645
   PubMed Web of Science ®Google Scholar
• JacobsLDBeckRWSimonJHIntramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. Champs Study GroupN Engl J Med20003431389890411006365
   PubMed Web of Science ®Google Scholar
• KapposLPolmanCHFreedmanMSTreatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesNeurology20066771242124916914693
   PubMed Web of Science ®Google Scholar
• ComiGMartinelliVRodegherMEffect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trialLancet200937497001503151119815268
   PubMed Web of Science ®Google Scholar
• KapposLFreedmanMSPolmanCHEffect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3 year follow-up analysis of the BENEFIT studyLancet2007370958538939717679016
   PubMed Web of Science ®Google Scholar
• KinkelRPKollmanCO’ConnorPIM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating eventNeurology200666567868416436649
   PubMed Web of Science ®Google Scholar
• HauserSLOksenbergJRThe neurobiology of multiple sclerosis: genes, inflammation, and neurodegenerationNeuron2006521617617015227
   PubMed Web of Science ®Google Scholar
• DouglassLHJorgensenCLPregnancy and multiple sclerosisAm J Obstet Gynecol194855233233618897954
   PubMed Web of Science ®Google Scholar
• PolmanCHRudickRAThe multiple sclerosis functional composite: a clinically meaningful measure of disabilityNeurology201074Suppl 3S8S1520421572
   PubMed Web of Science ®Google Scholar
• MillerDRudickRAHutchinsonMPatient-centered outcomes: translating clinical efficacy into benefits on health-related quality of lifeNeurology201074Suppl 3S24S3520421570
   PubMed Web of Science ®Google Scholar
• ManganoKNicolettiAPattiFVariable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitisClin Exp Immunol2009159215916819922500
   PubMed Web of Science ®Google Scholar
• BettelliEPaganyMWeinerHLMyelin oligodendrocyte glycoprotein-specif ic T cell receptor transgenic mice develop spontaneous autoimmune optic neuritisJ Exp Med200319791073108112732654
   PubMed Web of Science ®Google Scholar
• ZamvilSNelsonPTrotterJT-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelinationNature198531760353553582413363
   PubMed Web of Science ®Google Scholar
• GoldRLiningtonCLassmannHUnderstanding the pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis researchBrain2006129Pt 81953197116632554
   PubMed Web of Science ®Google Scholar
• van der WaltAButzkuevenHKolbeSNeuro-protection in multiple sclerosis: a therapeutic challenge for the next decadePharmacol Ther20101261829320122960
   PubMed Web of Science ®Google Scholar
• AscherioAMungerKLEnvironmental risk factors for multiple sclerosis. Part I: the role of infectionAnn Neurol200761428829917444504
   PubMed Web of Science ®Google Scholar
• PeltonenLOld suspects found guilty–the first genome profile of multiple sclerosisN Engl J Med2007357992792917660531
   PubMed Web of Science ®Google Scholar
• The International Multiple Sclerosis Genetics ConsortiumHaflerDACompstonARisk alleles for multiple sclerosis identified by a genomewide studyN Engl J Med2007357985186217660530
   PubMed Web of Science ®Google Scholar
• OksenbergJRBaranziniSESawcerSHauserSLThe genetics of multiple sclerosis: SNPs to pathways to pathogenesisNat Rev Genet20089751652618542080
   PubMed Web of Science ®Google Scholar
• SteinmanLMartinRBernardCConlonPOksenbergJRMultiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapyAnnu Rev Neurosci20022549150512052918
   PubMed Web of Science ®Google Scholar
• SospedraMMartinRImmunology of multiple sclerosisAnnu Rev Immunol20052368374715771584
   PubMed Web of Science ®Google Scholar
• FrohmanEMRackeMKRaineCSMultiple sclerosis–the plaque and its pathogenesisN Engl J Med2006354994295516510748
   PubMed Web of Science ®Google Scholar
• StuveOKnowns and unknowns in the future of multiple sclerosis treatmentJ Neurol Sci2009287Suppl 1S30S3620106346
   PubMed Web of Science ®Google Scholar
• LusterADAlonRvon AndrianUHImmune cell migration in inflammation: present and future therapeutic targetsNat Immunol20056121182119016369557
   PubMed Web of Science ®Google Scholar
• RudickRAStuartWHCalabresiPANatalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med2006354991192316510745
   PubMed Web of Science ®Google Scholar
• SteinmanLA molecular trio in relapse and remission in multiple sclerosisNat Rev Immunol20099644044719444308
   PubMed Web of Science ®Google Scholar
• MurugaiyanGMittalAWeinerHLIncreased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosisJ Immunol2008181117480748819017937
   PubMed Web of Science ®Google Scholar
• BettelliEOukkaMKuchrooVKTH-17 cells in the circle of immunity and autoimmunityNat Immunol20078434535017375096
   PubMed Web of Science ®Google Scholar
• HurEMYoussefSHawsMEZhangSYSobelRASteinmanLOsteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cellsNat Immunol200681748317143274
   PubMed Web of Science ®Google Scholar
• ChabasDBaranziniSEMitchellDThe influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelination diseaseScience200129455471731173511721059
   PubMed Web of Science ®Google Scholar
• SinclairCMirakhurMKirkJFarrellMMcQuaidSUp-regulation of osteopontin and αβ-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarraysNeuropathol Appl Neurobiol200531329230315885066
   PubMed Web of Science ®Google Scholar
• HanMHHwangSIRoyDBProteomic analysis of active multiple sclerosis lesions reveals therapeutic targetsNature200845171821076108118278032
   PubMed Web of Science ®Google Scholar
• OusmanSSTomookaBHvan NoortJMProtective and therapeutic role for αβ-crystallin in autoimmune demyelinationNature2007448715247447917568699
   PubMed Web of Science ®Google Scholar
• O’ConnorKCBar-OrAHaflerDAThe neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesisJ Clin Immunol2001212819211332657
   PubMed Web of Science ®Google Scholar
• TrappBDPetersonJRansohoffRMRudickRMorkSBoLAxonal transection in the lesions of multiple sclerosisN Engl J Med199833852782859445407
   PubMed Web of Science ®Google Scholar
• ButovskyOLandaGKunisGInduction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosisJ Clin Invest2006116490591516557302
   PubMed Web of Science ®Google Scholar
• CranerMJHainsBCLoACBlackJAWaxmanSGCo-localization of sodium channels Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAEBrain2004127Pt 229430314662515
   PubMed Web of Science ®Google Scholar
• DuttaRMcDonoughJYinXMitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patientsAnn Neurol200659347848916392116
   PubMed Web of Science ®Google Scholar
• OuardouzMCoderreEZamponiGWGlutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptorsAnn Neurol200965216016619224531
   PubMed Web of Science ®Google Scholar
• DrewPDChavisJABhattRSex steroid regulation of microglial cell activation: relevance to multiple sclerosisAnn N Y Acad Sci2003100732933414993065
   PubMed Web of Science ®Google Scholar
• McClainMAGatsonNNPowellNDPregnancy suppresses experimental autoimmune encephalomyelitis through immunoregulatory cytokine productionJ Immunol2007179128146815218056357
   PubMed Web of Science ®Google Scholar
• KimSLivaSMDalalMAVerityMAVoskuhlRREstriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosisNeurology19995261230123810214749
   PubMed Web of Science ®Google Scholar
• MoralesLBLooKKLiuHBPetersonCTiwari-WoodruffSVoskuhlRRTreatment with an estrogen receptor α ligand is neuroprotective in experimental autoimmune encephalomyelitisJ Neurosci200626256823683316793889
   PubMed Web of Science ®Google Scholar
• ZhuWHLuCZHuangYMLinkHXiaoBGA putative mechanism of remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2,3-dioxygenase by dendritic cellsMult Scler2007131334017294609
   PubMed Web of Science ®Google Scholar
• BakerAEBrautigamVMWattersJJEstrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor βEndocrinology2004145115021503215256495
   PubMed Web of Science ®Google Scholar
• OffnerHNeuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosisJ Neurosci Res200478560362415515048
   PubMed Web of Science ®Google Scholar
• StraubRHThe complex role of estrogens in inflammationEndocr Rev200728552157417640948
   PubMed Web of Science ®Google Scholar
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a mutlicenter, randomized, double-blind, placebo-controlled trialThe IFNB Multiple Sclerosis Study GroupNeurology19934346556618469318
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupAnn Neurol19963932852948602746
   PubMed Web of Science ®Google Scholar
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisPRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupLancet19983529139149815049820297
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology1995457126812767617181
   PubMed Web of Science ®Google Scholar
• CoylePKDisease-modifying agents in multiple sclerosisAnn Indian Acad Neurol200912427328220182575
   PubMed Web of Science ®Google Scholar
• GoodinDSFrohmanEMGarmanyGPJrDisease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice GuidelinesNeurology200258216917811805241
   PubMed Web of Science ®Google Scholar
• SorensenPSDeisenhammerFDudaPGuidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosisEur J Neurol2005121181782716241970
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis SocietyUpdate on Tysabri and PML: sponsor and FDA provide information on cases and risks Available from: http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=2308/Accessed Jun 29 2010
   Google Scholar
• US. Food and Drug AdministrationFDA drug safety communication: risk of progressive multifocal leukoencephalopathy (PML) with the use of Tysabri (natalizumab) Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199872.htm/Accessed Jun 29 2010
   Google Scholar
• DangondFMultiple sclerosiseMedicine Neurology2010 Available from: http://emedicine.medscape.com/article/1146199-print
   Google Scholar
• MillerDHLearySMPrimary progressive multiple sclerosisLancet Neurol200761090391217884680
   PubMed Web of Science ®Google Scholar
• FujinoMFuneshimaNKitazawaYAmelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatmentJ Pharmcol Exp Ther200330517077
   PubMed Web of Science ®Google Scholar
• O’ConnorPComiGMontalbanXOral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension studyNeurology2009721737919122034
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• GiovannoniGComiGCookSA Placebo-controlled trial of oral cladribine for relapsing multiple sclerosis [phase III]N Engl J Med2010362541642620089960
   PubMed Web of Science ®Google Scholar
• HawkerKO’ConnorPFreedmanMSRituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialAnn Neurol200966446047119847908
   PubMed Web of Science ®Google Scholar
• O’ConnorPWLiDFreedmanMSA Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology200666689490016567708
   PubMed Web of Science ®Google Scholar
• ComiGPulizziARovarisMEffect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837196302085209218572078
   PubMed Web of Science ®Google Scholar
• KapposLGoldRMillerDHEfficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837296481463147218970976
   PubMed Web of Science ®Google Scholar
• CAMMS223 Trial InvestigatorsColesAJCompstonDAAlemtuzumab vs interferon beta-1a in early multiple sclerosisN Engl J Med2008359171786180118946064
   PubMed Web of Science ®Google Scholar
• HauserSLWaubantEArnoldDLB-cell depletion with rituximab in relapsing-remitting multiple sclerosisN Engl J Med2008358767668818272891
   PubMed Web of Science ®Google Scholar
• BielekovaBHowardTPackerANEffect of anti-CD25 anti-body daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosisArch Neurol200966448348919364933
   PubMed Web of Science ®Google Scholar
• TallantyreEEvangelouNConstantinescuCSSpotlight on teriflunomideInt MS J2008152626818782502
   PubMedGoogle Scholar
• SalemiGCallariGGamminoMThe relapse rate of multiple sclerosis changes during pregnancy: a cohort studyActa Neurol Scand20041101232615180803
   PubMed Web of Science ®Google Scholar
• VukusicSHutchinsonMHoursMPregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapseBrain2004127Pt 61353136015130950
   PubMed Web of Science ®Google Scholar
• SicotteMLLivaSMKlutchRTreatment of multiple sclerosis with the pregnancy hormone estiolAnn Neurol200252442142812325070
   PubMed Web of Science ®Google Scholar
• SoldanSSAlvarez RetuertoAISicotteNLVoskulRRImmune modulation in multiple sclerosis patients treated with the pregnancy hormone estriolJ Immunol2003171116267627414634144
   PubMed Web of Science ®Google Scholar
• BurtRKLohYPearceWClinical applications of blood-derived and marrow-derived stem cells for non-malignant diseaseJAMA2008299892593618314435
   PubMed Web of Science ®Google Scholar
• MuraroPADouekDCPackerAThymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patientsJ Exp Med2005201580581615738052
   PubMed Web of Science ®Google Scholar
• NashRABowenJDMcSweeneyPAHigh-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosisBlood200310272364237212763935
   PubMed Web of Science ®Google Scholar
• BurtRKCohenBARussellEHematopoietic stem cell transplantation for progressive multiple sclerosis: failure of total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scoresBlood200310272373237812842989
   PubMed Web of Science ®Google Scholar
• OpenshawHLundBTKashyapAPeripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoringBiol Blood Marrow Transplant200065A56357511071262
   PubMed Web of Science ®Google Scholar
• FassasAPasswegJRAnagnostopoulosAHematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter studyJ Neurol200224981088109712195460
   PubMed Web of Science ®Google Scholar
• CarrerasESaizAMarinPCD34+ selected autologous peripheral blood stem cell transplantation for multiple slcerosis: report of toxicity and treatment results at one year follow-up in 15 patientsHaematologica200388330631412651270
   PubMed Web of Science ®Google Scholar
• CapelloESaccardiRMurialdoAIntense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosisNeurol Sci200526Suppl 4S200S20316388358
   PubMed Web of Science ®Google Scholar
• XuJJiBXSuLDongHQSunXJLiuCYClinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosisChin Med J (Engl)2006119221851185517134581
   PubMed Web of Science ®Google Scholar
• MancardiGLSaccardiRFilippiMAutologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MSNeurology2001571626811445629
   PubMed Web of Science ®Google Scholar
• SorensenPSMellgrenSISvenningssonANORdic trial of oral methylprednisoloine as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting multiple sclerosis (NORMIMS study): a randomised, placebo-controlled trialLancet Neurol20098651952919409854
   PubMed Web of Science ®Google Scholar
• RavnborgMSorensenPSAnderssonMMethylprednisolone in combination with interferon β-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trialLancet Neurol20109767268020542736
   PubMed Web of Science ®Google Scholar
• CohenJAImreyPBCalabresiPAResults of Avonex Combination Trial (ACT) in relapsing-remitting MSNeurology200972653554119204263
   PubMed Web of Science ®Google Scholar
• HavrdovaEZivadinovRKrasenskyJRandomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosisMult Scler200915896597619465443
   PubMed Web of Science ®Google Scholar
• GoodmanADRossmanHBar-OrAGLANCE: results of a phase 2, randomized, double-blind, placebo-controlled studyNeurology200972980681219255407
   PubMed Web of Science ®Google Scholar
• PattiFAmatoMPFilippiMGalloPTrojanoMComiGCA double blind, placebo-controlled, phase II, add-on study of cyclophosamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLINJ Neurol Sci20042231697115261564
   PubMed Web of Science ®Google Scholar
• CorrealeJRushCAmengualAGoicocheaMTMitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-βJ Neuroimmunol20051621217318315833353
   PubMed Web of Science ®Google Scholar
• RamtahalJJacobADasKBoggildMSequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immune-suppression in very active, relapsing remitting multiple sclerosisJ Neurol200625391160116416990994
   PubMed Web of Science ®Google Scholar
• ConwayDCohenJACombination therapy in multiple sclerosisLancet Neurol20109329930820170843
   PubMed Web of Science ®Google Scholar
• SchapiroRTManaging symptoms of multiple sclerosisNeurol Clin2005231177187vii15661093
   PubMed Web of Science ®Google Scholar
• Loss of mobility found to impact quality of life and emotional and financial health of most people living with multiple sclerosisNational Multiple Sclerosis Society [news release on the Internet]New YorkNational Multiple Sclerosis Society3200825 Available from: http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=199Accessed Jun 1 2010
   Google Scholar
• BainbridgeJLCorboyJRMultiple sclerosisDiPiroJTTalbertRLYeeGCMatzkeGRWellsBGPoseyLMPharmacotherapy: A Pathophysiologic Approach7th edNew York (NY)McGraw-Hill2008913
   Google Scholar
• JudgeSIBeverCTJrPotassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatmentPharmacol Ther2006111122425916472864
   PubMed Web of Science ®Google Scholar
• KorenkeARRiveyMPAllingtonDRSustained-release fampridine for symptomatic treatment of multiple sclerosisAnn Pharmacother200842101458146518780812
   PubMed Web of Science ®Google Scholar
• GoodmanADBrownTRKruppLBSustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialLancet2009373966573273819249634
   PubMed Web of Science ®Google Scholar
• GoodmanADBrownTRCohenJADose comparison trial of sustained-release fampridine in multiple sclerosisNeurology200871151134114118672472
   PubMed Web of Science ®Google Scholar
• GoodmanADCohenJACrossAFampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging studyMult Scler200713335736817439905
   PubMed Web of Science ®Google Scholar
• Acorda TherapeuticsAcorda Therapeutics announces positive data from second Phase 3 study of fampridine-SR on walking ability in people with multiple sclerosis Available from: http://phoenix.corporate-ir.net/phoenix.zhtml?c=194451&p=irolnewsArticle&ID=1160986&highlightAccessed Jun 1 2010
   Google Scholar
• Acorda Therapeutics IncFampridine-SR Advisory Committee briefing document. Fampridine-SR tablets for improvement in walking ability in patients with multiple sclerosisPeripheral and Central Nervous System Drugs Advisory Committee Meeting2009 Oct 14 NDA22-250. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM185664.pdfAccessed Jun 20 2010
   Google Scholar
• GoodmanADBrownTKruppLInterim analysis of an open-label extension study of sustained release fampridine in patients with multiple sclerosis [abstract]Mult Scler200915Suppl 2S13
   Google Scholar
• GoodmanADBrownTREdwardsKRInterim analysis of open-label extension studies of dalfampridine extended release tablets in patients with multiple sclerosis [Abstract S01008]Proceedings of the American Academy of Neurology 2010 Annual Meeting2010 Apr 13Toronto, Canada Abstract available from: http://www.abstracts2view.com/aan/view.php?nu=AAN10L_S01.008Accessed Jun 8 2010
   Google Scholar
• SchwidSRPetrieMDMcDermottMPTierneyDSMasonDHGoodmanADQuantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosisNeurology19974848178219109861
   PubMed Web of Science ®Google Scholar
• Sanofi-AventisEfficacy, safety, and tolerability of nerispirdine in patients with multiple sclerosis Last updated 2010 Mar 22 ClinicalTrials. gov Web site. Available from: http://clinicaltrials.gov/ct2/show/NCT00811902Accessed Apr 9 2010
   Google Scholar
• SmithCKongsamutSWangHJiJKangJRampeDIn vitro electrophysiological activity of nerispirdine, a novel 4-aminopyridine derivativeClin Exp Pharmacol Physiol200936111104110919413590
   PubMed Web of Science ®Google Scholar
• LangeRVolkmerMHeesenCLiepertJModafinil effects in multiple sclerosis patients with fatigueJ Neurol2009256464565019367356
   PubMed Web of Science ®Google Scholar
• BrownJNHowardCAKempDWModafinil for the treatment of multiple sclerosis-related fatigueAnn Pharmacother20104461098110320442351
   PubMed Web of Science ®Google Scholar
• StankoffBWaubantEConfavreuxCModafinil for fatigue in MS: a randomized placebo-controlled double-blind studyNeurology20056471139114315824337
   PubMed Web of Science ®Google Scholar
• FDA approves Botox® for treating spasticity, or tightness, in upper limbsNational Multiple Sclerosis Society [news release on the Internet]New YorkNational Multiple Sclerosis Society2010312 Available from: http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=2875Accessed May 17 2010
   Google Scholar
• SmithPFNew approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoidsTher Clin Risk Manag20106596320234785
   PubMed Web of Science ®Google Scholar
• ChristodoulouCMelvillePScherlWFMacallisterWSElkinsLEKruppLBEffects of donepezil on memory and cognition in multiple sclerosisJ Neurol Sci200624512127136
   Web of Science ®Google Scholar
• ShaygannejadVJanghorbaniMAshtariFZanjaniHAZakizadeNEffects of rivastigmine on memory and cognition in multiple sclerosisCan J Neurol Sci200835447648118973065
   PubMed Web of Science ®Google Scholar
• MorrowSAKaushikTZarevicsPThe effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trialJ Neurol200925671095110219263186
   PubMed Web of Science ®Google Scholar
• LoveraJFFrohmanEBrownTRMemantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trialMult Scler201016671572320483885
   PubMed Web of Science ®Google Scholar
• KleinschnitzCMEuthSGKieseierBCWiendlHImmunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006Endocr Metab Immune Disord Drug Targets200771356317346203
   PubMedGoogle Scholar
• LinkerRAKieseierBCGoldRIdentification and development of new therapeutics for multiple sclerosisTrends Pharmacol Sci2008291155856518804288
   PubMed Web of Science ®Google Scholar